FDA Delays Leqembi Subcutaneous Starting Dose Review to August 2026
The FDA extended its priority review for a weekly injectable Alzheimer's drug by three months, with no approvability concerns raised.
Summary
The FDA has extended its priority review for a subcutaneous (under-skin) starting dose of lecanemab, the Alzheimer's drug sold as Leqembi, pushing the decision deadline to August 24, 2026. Makers Eisai and Biogen say the agency requested additional information, triggering a standard three-month extension. Importantly, the FDA has not raised any concerns about whether the drug can be approved. A weekly self-injectable maintenance dose of the same drug already received U.S. approval in August 2025. Leqembi works by clearing amyloid plaques from the brain and has been approved in 53 countries. Patients and caregivers should note that the drug carries risks including brain swelling and bleeding, and genetic testing for ApoE ε4 status is recommended before starting treatment.
Detailed Summary
Lecanemab, marketed as Leqembi, is one of the few FDA-approved therapies that targets the underlying biology of Alzheimer's disease by clearing amyloid plaques from the brain. Its potential shift to a convenient once-weekly subcutaneous injection — rather than intravenous infusion — represents a meaningful step toward broader accessibility for patients with early Alzheimer's disease.
The FDA has extended its priority review of the supplemental biologics license application for a subcutaneous starting dose by three months, moving the PDUFA action date from May to August 24, 2026. The extension was triggered by a request for additional information from regulators, which legally qualifies as a major amendment and requires extra review time. Crucially, the FDA has not signaled any approvability concerns, suggesting the delay is procedural rather than a red flag.
This update builds on an earlier milestone: the subcutaneous maintenance dose of Leqembi already received U.S. approval in August 2025. The current application seeks approval for a starting dose regimen delivered the same way, which would allow patients to begin and continue treatment entirely via self-injection at home, eliminating the burden of clinic-based IV infusions.
Leqembi has now been approved in 53 countries and regions, reflecting broad global regulatory acceptance of its clinical data. Eisai and Biogen argue their comprehensive clinical package supports the starting dose application on the strength of the existing maintenance approval.
Key caveats remain. The drug carries a risk of amyloid-related imaging abnormalities (ARIA) — brain swelling and microbleeds — which can be serious. Patients who carry two copies of the ApoE ε4 gene face a significantly higher risk and require genetic testing before starting therapy. Anyone considering lecanemab should discuss their genetic status, cardiovascular history, and risk tolerance thoroughly with a neurologist before proceeding.
Key Findings
- FDA extended Leqembi subcutaneous starting dose review by three months to August 24, 2026.
- No approvability concerns have been raised by the FDA; delay is procedural.
- Subcutaneous maintenance dosing for Leqembi already approved in the U.S. since August 2025.
- ApoE ε4 homozygotes face higher ARIA risk; genetic testing required before initiating treatment.
- Leqembi is now approved in 53 countries, supporting its broad clinical evidence base.
Methodology
This is a regulatory news report based on an official press announcement from Eisai and Biogen. The source, Longevity.Technology, is a credible science news outlet covering aging and therapeutics. Evidence basis is a corporate press release, not a peer-reviewed study.
Study Limitations
This article is based solely on a company press release and does not include independent expert commentary or primary clinical data. The three-month review extension introduces uncertainty about final approval timing and label details. Patients should consult neurologists and await the full FDA decision before making treatment decisions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.